

# Contents in Print

Preface ..... ix

---

## QUALITY AND RELATED ISSUES

### **1. Quality Management Systems: Principles and Practice ..... 1**

*Patricia C. Grace, RN, BSN, and Jamie Buetow, MT(ASCP)SH*

Key Points ..... 1  
Background ..... 3  
Concepts in Quality ..... 3  
Quality Management Systems Approach ..... 5  
Evaluation of the Quality Management System ..... 6  
The Quality Management System in Practice ..... 7  
References ..... 25  
Appendix 1-1. Glossary of Commonly Used Quality Terms ..... 26  
Appendix 1-2. Code of Federal Regulations Quality-Related References ..... 28  
Appendix 1-3. Suggested Quality Control Performance Intervals for  
Equipment and Reagents ..... 29

### **2. Facilities, Work Environment, and Safety .....33**

*Colleen Bowman, MT(ASCP)SBB, CQA(ASQ), and Jovona Powelson, BS,  
MLT(ASCP)*

Key Points ..... 33  
Facilities ..... 34  
Safety Program ..... 36  
Fire Prevention ..... 40  
Electrical Safety ..... 41  
Biosafety ..... 41  
Chemical Safety ..... 49  
Radiation Safety ..... 54  
Shipping Hazardous Materials ..... 57  
General Waste Management ..... 57  
References ..... 58  
Appendix 2-1. Safety Regulations and Recommendations Applicable to  
Health-Care Settings ..... 61

|   |    |
|---|----|
| Appendix 2-2. General Guidance for Safe Work Practices, Personal Protective Equipment, and Engineering Controls . . . . . | 63 |
| Appendix 2-3. Biosafety Level 2 Precautions . . . . .   | 67 |
| Appendix 2-4. Sample List of Hazardous Chemicals That May Be Encountered in a Blood Bank . . . . .                        | 68 |
| Appendix 2-5. Chemical Categories and How to Work Safely with Them . . . . .  | 70 |
| Appendix 2-6. Incidental Spill Response . . . . .   | 72 |
| Appendix 2-7. Managing Hazardous Chemical Spills . . . . .  | 75 |

### **3. Regulatory Considerations in Transfusion Medicine and Biotherapies . . . . . 77**

*Robert A. DeSimone, MD, and Yvette C. Tanhehco, PhD, MD, MS*

|  |    |
|--|----|
| Key Points . . . . .   | 77 |
| FDA Oversight of Blood Establishments . . . . .                        | 78 |
| Medical Laboratory Laws and Regulations . . . . .                      | 85 |
| Local Laws, Hospital Regulations, and Accreditation . . . . .          | 86 |
| Human Cells, Tissues, and Cellular and Tissue-Based Products . . . . . | 86 |
| References . . . . .   | 91 |

### **4. National Hemovigilance: Past, Present, and Future . . . . . 95**

*Mary Townsend, MD; Barbee I. Whitaker, PhD; and Lynne Uhl, MD*

|  |     |
|--|-----|
| Key Points . . . . .   | 95  |
| Biovigilance . . . . .   | 96  |
| International Hemovigilance—Origins of a New Concept . . . . .                                 | 98  |
| US Hemovigilance—A Concept Takes Root . . . . .  | 99  |
| The Future: International Collaborations . . . . .   | 107 |
| Next Steps in US Hemovigilance . . . . .   | 108 |
| References . . . . .   | 109 |
| Appendix 4-1. Template Form for Hospital Reporting Adverse Events to Blood Suppliers . . . . . | 112 |
| Appendix 4-2. Severity Grading Tool for Blood Donor Adverse Events . . . . .                   | 120 |

---

## B L O O D C O L L E C T I O N A N D T E S T I N G

### **5. Allogeneic and Autologous Blood Donor Selection . . . . . 123**

*Susan N. Rossmann, MD, PhD, and Richard R. Gammon, MD*

|  |     |
|--|-----|
| Key Points . . . . .   | 123 |
| Overview of Blood Donor Screening . . . . .                            | 124 |
| Selection of Allogeneic Blood Donors . . . . .                         | 125 |
| Abbreviated DHQ for Frequent Donors . . . . .                          | 129 |
| Blood-Center-Defined Donor Eligibility Criteria . . . . .              | 130 |
| Recipient-Specific “Designated” or “Directed” Blood Donation . . . . . | 132 |
| References . . . . .   | 134 |

## **6. Whole Blood and Apheresis Collection of Blood Components Intended for Transfusion . . . . . 137**

*Jason Acker, MBA, PhD; Anna Razatos, PhD; and Denese Marks, PhD*

|  |     |
|--|-----|
| Key Points . . . . .   | 137 |
| Donor Preparation and Care . . . . .                             | 138 |
| Blood Collection . . . . .                                       | 142 |
| Blood Component Storage . . . . .                                | 150 |
| Postcollection Processing/Blood Component Modification . . . . . | 156 |
| Quarantine of Blood Components . . . . .                         | 160 |
| Labeling of Blood Components . . . . .                           | 160 |
| References . . . . .   | 162 |

## **7. Infectious Disease Screening . . . . . 169**

*Lauren A. Crowder, PhD, MPH, and Paula Saá, PhD*

|  |     |
|--|-----|
| Key Points . . . . .                                   | 169 |
| Historical Overview of Blood Donor Screening . . . . . | 170 |
| Donor Screening Tests . . . . .                        | 174 |
| Residual Infectious Risks of Transfusion . . . . .     | 192 |
| Screening for Specific Agents . . . . .                | 194 |
| Pathogen Reduction Technology . . . . .                | 211 |
| Summary . . . . .                                      | 213 |
| References . . . . .                                   | 214 |

---

### B L O O D   G R O U P S

## **8. Molecular Biology and Immunology in Transfusion Medicine . . . . . 225**

*Celina Montemayor, MD, PhD, and William J. Lane, MD, PhD, A(ACHI)*

|                                     |     |
|-------------------------------------|-----|
| Key Points . . . . .                | 225 |
| Analysis of Nucleic Acids . . . . . | 226 |
| Analysis of Protein . . . . .       | 236 |
| Basic Immunology . . . . .          | 242 |
| References . . . . .                | 249 |

## **9. Blood Group Genetics . . . . . 255**

*Michael S. Gannett, MLS(ASCP)<sup>CM</sup>SBB<sup>CM</sup>, and Margaret A. Keller, PhD*

|  |     |
|--|-----|
| Key Points . . . . .                               | 255 |
| Genomic Organization and Gene Regulation . . . . . | 257 |
| Genetic Variation . . . . .                        | 266 |
| Inheritance of Genetic Traits . . . . .            | 268 |
| Structural Variation . . . . .                     | 274 |
| Chimerism . . . . .                                | 275 |
| Gene Position Effects . . . . .                    | 276 |

|  |     |
|--|-----|
| Genetic Modifiers of Blood Group Antigen Expression . . . . .          | 276 |
| Population Genetics . . . . .  | 277 |
| Relationship Testing . . . . .   | 280 |
| Blood Group Gene Mapping . . . . .                                     | 281 |
| Gene, Protein, and Blood Group Terminology . . . . .                   | 282 |
| Blood Group Genomics . . . . .   | 283 |
| Summary . . . . .  | 293 |
| References . . . . .   | 294 |
| Appendix 9-1. Glossary of Terms Used in Blood Group Genetics . . . . . | 299 |

## 10. **ABO and Other Carbohydrate Blood Group Systems . . . . . 303**

*Connie M. Arthur, PhD; Martin L. Olsson, MD, PhD; and Sean R. Stowell, MD, PhD*

|  |     |
|--|-----|
| Key Points . . . . .   | 303 |
| The ABO System (001) . . . . .   | 304 |
| The H System (018) . . . . .   | 318 |
| The LE System (007) . . . . .  | 321 |
| I Antigen of the I Blood Group System (027) and I Antigen of the Ii Blood Group Collection . . . . . | 323 |
| P1PK (003) and GLOB (028) Blood Group Systems . . . . .  | 326 |
| The FORS Blood Group System (031) . . . . .  | 331 |
| The SID Blood Group System (038) . . . . .   | 331 |
| References . . . . .   | 331 |

## 11. **The Rh System . . . . . 337**

*Sunitha Vege, MS; Thierry Peyrard, PharmD, PhD, EurSpLM; and Franz F. Wagner, MD*

|   |     |
|---|-----|
| Key Points . . . . .  | 337 |
| Historical Perspective . . . . .  | 338 |
| Terminology . . . . .   | 341 |
| Rh Locus . . . . .  | 342 |
| RHD Genotype . . . . .  | 344 |
| Antigens . . . . .  | 344 |
| Rh Genotyping . . . . .   | 357 |
| Rh <sub>null</sub> Syndrome and the RhAG (030) Blood Group System . . . . . | 358 |
| Antibodies to Rh Blood Group System Antigens . . . . .                      | 358 |
| Technical Considerations for Rh Typing . . . . .                            | 359 |
| References . . . . .  | 361 |

## 12. **Other Blood Group Systems and Antigens . . . . . 367**

*Cami Melland, MLS(ASCP)<sup>CM</sup>SBB, and Michelle Palk, MT(ASCP)SBB*

|  |     |
|--|-----|
| Key Points . . . . .                         | 367 |
| The MNS System (002) . . . . .               | 368 |
| The LU System (005) . . . . .                | 377 |
| The KEL (006) and Xk (019) Systems . . . . . | 379 |
| The FY System (008) . . . . .                | 382 |

|   |     |
|---|-----|
| The JK System (009) . . . . .                                     | 384 |
| The DI System (010) . . . . .                                     | 386 |
| The YT System (011) . . . . .                                     | 387 |
| The XG System (012) . . . . .                                     | 388 |
| The SC System (013) . . . . .                                     | 388 |
| The DO System (014) . . . . .                                     | 388 |
| The CO System (015) . . . . .                                     | 389 |
| The LW System (016) . . . . .                                     | 390 |
| The CH/RG System (017) . . . . .                                  | 391 |
| The GE System (020) . . . . .                                     | 391 |
| The CROM System (021) . . . . .                                   | 392 |
| The KN System (022) . . . . .                                     | 392 |
| The IN System (023) . . . . .                                     | 393 |
| The OK System (024) . . . . .                                     | 393 |
| The RAPH System (025) . . . . .                                   | 394 |
| The JMH System (026) . . . . .                                    | 394 |
| The GIL System (029) . . . . .                                    | 394 |
| The RHAG System (030) . . . . .                                   | 394 |
| The JR System (032) . . . . .                                     | 395 |
| The LAN System (033) . . . . .                                    | 395 |
| The VEL System (034) . . . . .                                    | 395 |
| The CD59 System (035) . . . . .                                   | 395 |
| The AUG System (036) . . . . .                                    | 396 |
| The KANNO System (037) . . . . .                                  | 396 |
| The CTL2 System (039) . . . . .                                   | 396 |
| The PEL System (040) . . . . .                                    | 396 |
| The MAM System (041) . . . . .                                    | 397 |
| The EMM System (042) . . . . .                                    | 397 |
| The ABCC1 System (043) . . . . .                                  | 397 |
| The ER System (044) . . . . .                                     | 397 |
| Antigens That Do Not Yet Belong to a Blood Group System . . . . . | 397 |
| References . . . . .  | 399 |

### **13. Identification of Antibodies to Red Cell Antigens . . . . . 405**

*Jennifer O'Connor, MSTM, MLS(ASCP)CMSBB<sup>CM</sup>, and Lay See Er, MSTM, SBB(ASCP)<sup>CM</sup>, CQA(ASQ)*

|  |     |
|--|-----|
| Key Points . . . . .                                       | 405 |
| Basic Concepts in Red Cell Antigen Expression . . . . .    | 407 |
| Initial Antibody Identification Considerations . . . . .   | 408 |
| Basic Antibody Identification . . . . .                    | 411 |
| Complex Antibody Identification . . . . .                  | 419 |
| Selected Procedures . . . . .                              | 431 |
| Considerations Following Antibody Identification . . . . . | 438 |
| Immunohematology Reference Laboratories . . . . .          | 441 |
| References . . . . .                                       | 441 |
| Suggested Readings . . . . .                               | 444 |

## **14. The Positive Direct Antiglobulin Test and Immune-Mediated Hemolysis..... 447**

*Paul M. Mansfield, MT(ASCP)SBB<sup>CM</sup>, and Shraddha Patel Babariya, MD*

|  |     |
|--|-----|
| Key Points .....   | 447 |
| The DAT .....  | 449 |
| Autoimmune Hemolytic Anemia .....                                  | 453 |
| Drug-Induced Immune Hemolytic Anemia .....                         | 464 |
| References .....   | 468 |
| Appendix 14-1. Drugs Associated with Immune Hemolytic Anemia ..... | 471 |

## **15. Platelet and Granulocyte Antigens and Antibodies ..... 475**

*Ulrich J. Sachs, MD, and Jürgen Bux, MD*

|   |     |
|---|-----|
| Key Points .....                          | 475 |
| Platelet Antigens and Antibodies .....    | 476 |
| Granulocyte Antigens and Antibodies ..... | 488 |
| References .....                          | 495 |

## **16. The HLA System ..... 503**

*Robert Liwski, MD, PhD, FRCPC, and Jeremy Ryan Peña, MD, PhD, MS*

|   |     |
|---|-----|
| Key Points .....  | 503 |
| Biochemistry, Tissue Distribution, and Structure .....  | 504 |
| Genetics of the MHC .....                               | 509 |
| HLA Typing .....  | 512 |
| Other Non-HLA Histocompatibility Determinants .....     | 515 |
| Crossmatching and Detection of HLA Antibodies .....     | 515 |
| The HLA System and Transfusion .....                    | 516 |
| HLA Testing and Transplantation .....                   | 519 |
| Other Clinically Significant Aspects of HLA .....       | 521 |
| Clinical Consultation in HLA .....                      | 522 |
| Regulatory Aspects of Clinical Histocompatibility ..... | 524 |
| Future Directions .....                                 | 524 |
| Summary .....   | 525 |
| References .....  | 525 |

---

### ESSENTIALS OF TRANSFUSION PRACTICE

## **17. Transfusion-Service-Related Activities: Pretransfusion Testing and Storage, Monitoring, Processing, Distribution, and Inventory Management of Blood Components..... 529**

*Tina S. Ipe, MD, MPH, and Caroline R. Alquist, MD, PhD*

|   |     |
|---|-----|
| Key Points .....                                | 529 |
| Samples and Requests .....                      | 530 |
| Pretransfusion Testing of Recipient Blood ..... | 531 |

|   |            |
|---|------------|
| Blood and Blood Component Storage and Monitoring . . . . .                                      | 536        |
| Pretransfusion Processing . . . . .   | 546        |
| Distribution . . . . .  | 550        |
| Issuing of Components . . . . .   | 551        |
| Inventory Management . . . . .  | 555        |
| References . . . . .  | 557        |
| Appendix 17-1. Sources of False-Positive Results in Antiglobulin Testing . . . . .              | 562        |
| Appendix 17-2. Sources of False-Negative Results in Antiglobulin Testing . . . . .              | 563        |
| Appendix 17-3. Causes of Positive Pretransfusion Test Results. . . . .                          | 565        |
| <br>  |            |
| <b>18. Administration of Blood Components and Biotherapies . . . . .</b>                        | <b>567</b> |
| <i>Sarah Vossoughi, MD, RN, and Monika Paroder, MD, PhD</i>                                     |            |
| Key Points . . . . .  | 567        |
| Considerations Before Dispensing Blood Components . . . . .                                     | 569        |
| Blood Component Transportation and Dispensing . . . . .   | 574        |
| Blood Administration . . . . .  | 575        |
| Documentation of the Transfusion . . . . .  | 579        |
| Unique Transfusion Settings . . . . .   | 579        |
| Administration of Cellular Therapy Car T-Cell Products . . . . .                                | 580        |
| Conclusion . . . . .  | 585        |
| References . . . . .  | 586        |
| <br>  |            |
| <b>19. Transfusion Therapy: Evidence and Recommendations<br/>for Clinical Practice. . . . .</b> | <b>589</b> |
| <i>Yunchuan Delores Mo, MD, and Cyril Jacquot, MD, PhD</i>                                      |            |
| Key Points . . . . .  | 589        |
| Red Blood Cell Transfusion . . . . .  | 590        |
| Platelet Transfusion . . . . .  | 598        |
| Plasma Transfusion . . . . .  | 605        |
| Cryoprecipitate Transfusion . . . . .   | 607        |
| Granulocyte Transfusion . . . . .   | 608        |
| Massive Transfusion Protocols . . . . .   | 609        |
| References . . . . .  | 611        |
| <br>  |            |
| <b>20. Patient Blood Management. . . . .</b>  | <b>623</b> |
| <i>Steven M. Frank, MD; Anil K. Panigrahi, MD, PhD; and Nicole R. Guinn,<br/>MD, MBA</i>        |            |
| Key Points . . . . .  | 623        |
| Definition and Scope of Patient Blood Management . . . . .                                      | 624        |
| Resources to Support a PBM Program . . . . .  | 625        |
| Patient Blood Management Standards and Certification . . . . .                                  | 626        |
| Methods of Patient Blood Management . . . . .   | 626        |
| Data Collection . . . . .   | 647        |
| Extremes of Transfusion . . . . .   | 649        |
| Summary . . . . .   | 651        |
| References . . . . .  | 651        |

## **21. Approaches to Auditing of Blood Utilization and Administration..... 659**

*Jay P. Hudgins, DO, MS; Opal L. Reddy, MD; and Meredith Reyes, MD*

|   |     |
|---|-----|
| Key Points .....  | 659 |
| The Auditing Process .....  | 660 |
| Defining Audit Criteria .....   | 662 |
| Types of Blood Utilization Review .....   | 664 |
| Blood Utilization Review of Transfusions to High-Risk Patients .....                        | 667 |
| The Role of a Computerized Provider Order Entry System in Blood Utilization Review .....    | 667 |
| Use of “Big Data” to Assess Performance and Progress Measures in Transfusion Medicine ..... | 668 |
| Audits for Administration of Blood and Cell Therapies .....                                 | 670 |
| References .....  | 671 |

---

### SPECIAL PATIENTS AND SITUATIONS

## **22. Noninfectious Complications of Blood Transfusion ..... 675**

*Richard O. Francis, MD, PhD, and Brie A. Stotler, MD, MPH*

|  |     |
|--|-----|
| Key Points .....   | 675 |
| Hemovigilance .....  | 676 |
| Recognition and Evaluation of a Suspected Transfusion Reaction ..... | 676 |
| Acute or Immediate Transfusion Reactions .....                       | 684 |
| Delayed Transfusion Reactions .....                                  | 698 |
| Fatality Reporting Requirements .....                                | 702 |
| References .....   | 703 |

## **23. Perinatal Issues in Transfusion Practice ..... 709**

*Jennifer Andrews, MD, MSc, and Gwen Clarke, MD*

|  |     |
|--|-----|
| Key Points .....                                 | 709 |
| Hemolytic Disease of the Fetus and Newborn ..... | 710 |
| Pregnancy-Related Thrombocytopenia .....         | 719 |
| References .....                                 | 722 |

## **24. Neonatal and Pediatric Transfusion Practice ..... 729**

*Ruchika Goel, MD, MPH; Rowena C. Punzalan, MD; and Edward C.C. Wong, MD*

|   |     |
|---|-----|
| Key Points .....  | 729 |
| Hematopoiesis, Coagulation, and Physiology .....                      | 730 |
| RBC Transfusion in Neonates .....                                     | 732 |
| RBC Transfusion in Infants Older Than 4 Months and Children .....     | 738 |
| Platelet Transfusion in Neonates and Children .....                   | 742 |
| Plasma and Cryoprecipitate Transfusion in Neonates and Children ..... | 744 |
| Granulocyte Transfusion in Neonates and Children .....                | 746 |



|  |            |
|--|------------|
| Other Considerations in Transfusing Neonates and Children . . . . .                              | 746        |
| Adverse Effects and Prevention . . . . .   | 750        |
| Future Research Directions for Pediatric and Neonatal Transfusion Medicine . . . . .             | 752        |
| References . . . . .   | 753        |
| <b>25. Therapeutic Apheresis . . . . .</b>   | <b>763</b> |
| <i>Nicole Dodge Zantek, MD, PhD, and Jennifer Webb, MD, MSCE</i>                                 |            |
| Key Points . . . . .   | 763        |
| General Principles . . . . .   | 764        |
| Device Modalities . . . . .  | 765        |
| Patient Evaluation and Management . . . . .  | 765        |
| Vascular Access . . . . .  | 768        |
| Anticoagulation . . . . .  | 769        |
| Adverse Events . . . . .   | 769        |
| Pediatric Apheresis . . . . .  | 771        |
| Therapeutic Apheresis Indications . . . . .  | 771        |
| Therapeutic Apheresis Procedure Documentation, Payment, and Provider<br>Credentialing . . . . .  | 787        |
| References . . . . .   | 788        |
| <b>26. Collection, Processing, and Issuance of Cellular<br/>  Biotherapies . . . . .</b>         | <b>797</b> |
| <i>Huy P. Pham, MD, MPH, and Laura S. Connelly-Smith, MBBCh, DM</i>                              |            |
| Key Points . . . . .   | 797        |
| Clinical Utility . . . . .   | 798        |
| Histocompatibility, Donor Type, and Graft Source For HSCT . . . . .                              | 801        |
| Collection . . . . .   | 804        |
| Processing Human Progenitor Cells . . . . .  | 810        |
| Specialized Cell-Processing Methods . . . . .  | 812        |
| Cryopreservation . . . . .   | 813        |
| Quality Control . . . . .  | 814        |
| Shipping and Transporting HPC Cellular Products . . . . .  | 816        |
| Patient Care . . . . .   | 817        |
| Regulatory and Accreditation Considerations . . . . .  | 818        |
| Conclusion . . . . .   | 819        |
| References . . . . .   | 820        |
| <b>27. Transfusion Support for Hematopoietic Stem Cell<br/>  Transplant Recipients . . . . .</b> | <b>831</b> |
| <i>Cheryl Goss, MD, and Monica B. Pagano, MD</i>   |            |
| Key Points . . . . .   | 831        |
| Pretransplantation . . . . .   | 832        |
| Peritransplantation . . . . .  | 833        |
| Postengraftment . . . . .  | 838        |
| Special Considerations . . . . .   | 839        |
| References . . . . .   | 841        |

**28. Adverse Reactions to Cellular Immunotherapies..... 845**

*Andrew D. Fesnak, MD, and Jay S. Raval, MD*

- Key Points ..... 845
- Reactions Associated With Effector Function ..... 846
- Insertional Mutagenesis ..... 851
- Risks of Allogeneic Therapy ..... 852
- Infusion Reactions Unrelated to the Primary Mechanism of Action ..... 852
- Conclusion ..... 853
- References ..... 854

**29. Human Tissue Allografts and the Hospital Transfusion Service ..... 857**

*Ljiljana V. Vasovic, MD, and Annette J. Schlueter, MD, PhD*

- Key Points ..... 857
- Tissue Donation and Transplantation ..... 858
- Federal Regulations, State Laws, and Professional Standards ..... 863
- Hospital Tissue Services ..... 865
- Transfusion Service Support For Organ Transplantation ..... 871
- References ..... 872

**Index ..... 875**

# Contents Online

[www.aabb.org/methods](http://www.aabb.org/methods)

---

M E T H O D S

